Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jan 8

PMID 36614243

Authors

Maria J Orea

Javier C Angulo

Ana Gonzalez-Corpas

David Echegaray

Marcos Marva

Maria V T Lobo

Begona Colas

Santiago Ropero

Affiliations

Soon will be listed here.

Abstract

Castration-resistant prostate cancer (CRPC) development is the foremost concern after treatment of patients with high risk with locally advanced or metastatic prostate cancer. Androgen receptor (AR) is the main driver of CRPC development, through its interaction with epigenetic modifier genes, placing epigenetics modifications in the forefront of CRPC development. Comparing the DNA methylation and expression profile of androgen-sensitive and -refractory prostate cancer cells, we describe the epigenetic silencing of claudin-3 (CLDN3) in AR positive cells resistant to androgen deprivation (LNCaP-abl). CLDN3 silencing was associated with DNA methylation, loss of histone acetylation and H3K27 methylation, and was re-expressed by the combined treatment with the epigenetic modulators Aza and SAHA. From a functional point of view, CLDN3 loss was associated with increased cellular invasion. Immunohistochemical analysis showed decreased CLDN3 expression in samples from CRPC patients. Interestingly, CLDN3 expression was significantly decreased in samples from patients with high total Gleason score (≥8) and locally advanced tumors. Finally, CLDN3 loss of expression was associated with worse disease-free survival and time to clinical progression. In conclusion, our findings strongly indicate that epigenetic silencing of CLDN3 is a common event in CRPC that could be useful as a molecular marker for the prognosis of prostate cancer patients and to discriminate aggressive from indolent prostate tumors.

Citing Articles

Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors.

Luo M, Wang X, Yu G, Ji J, Li L, Song F Exp Hematol Oncol. 2025; 14(1):33.

PMID: 40057807 PMC: 11889805. DOI: 10.1186/s40164-025-00624-9.

Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples.

Buyucek S, Schraps N, Menz A, Lutz F, Chirico V, Viehweger F Biomark Res. 2024; 12(1):154.

PMID: 39658782 PMC: 11633013. DOI: 10.1186/s40364-024-00702-w.

Identification of genome-wide copy number variation-driven subtypes for the treatment and prognostic prediction of esophageal carcinoma.

Zhao C, Han H, Tian Y, Qu G, Xu Y, Wang Y Heliyon. 2024; 10(19):e38011.

PMID: 39386821 PMC: 11462465. DOI: 10.1016/j.heliyon.2024.e38011.

Expression and Targeted Application of Claudins Family in Hepatobiliary and Pancreatic Diseases.

Du F, Xie Y, Wu S, Ji M, Dong B, Zhu C J Hepatocell Carcinoma. 2024; 11:1801-1821.

PMID: 39345937 PMC: 11439345. DOI: 10.2147/JHC.S483861.

Claudins in Cancer: A Current and Future Therapeutic Target.

Hana C, Thaw Dar N, Galo Venegas M, Vulfovich M Int J Mol Sci. 2024; 25(9).

PMID: 38731853 PMC: 11083183. DOI: 10.3390/ijms25094634.

References

Angulo J, Andres G, Ashour N, Sanchez-Chapado M, Lopez J, Ropero S . Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. J Urol. 2015; 195(3):619-26. DOI: 10.1016/j.juro.2015.10.172. View

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

Debnath S, Hao G, Guan B, Thapa P, Hao J, Hammers H . Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists. Int J Mol Sci. 2022; 23(13). PMC: 9266369. DOI: 10.3390/ijms23137160. View

Waltering K, Urbanucci A, Visakorpi T . Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol. 2012; 360(1-2):38-43. DOI: 10.1016/j.mce.2011.12.019. View

Wadosky K, Koochekpour S . Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016; 7(39):64447-64470. PMC: 5325456. DOI: 10.18632/oncotarget.10901. View

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J . Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57(2):314-9. View

Jiang L, Yang Y, Fu L, Xu W, Liu D, Liang Q . CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget. 2014; 5(17):7663-76. PMC: 4202152. DOI: 10.18632/oncotarget.2288. View

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

Gregory C, He B, Johnson R, Ford O, Mohler J, French F . A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61(11):4315-9. View

10.

Moehren U, Papaioannou M, Reeb C, Hong W, Baniahmad A . Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol. 2007; 21(5):1039-48. DOI: 10.1210/me.2006-0468. View

11.

Ashour N, Angulo J, Gonzalez-Corpas A, Orea M, Lobo M, Colomer R . Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: a Role Regulating Tumor Growth. Int J Mol Sci. 2020; 21(13). PMC: 7370116. DOI: 10.3390/ijms21134687. View

12.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

13.

Di Cello F, Cope L, Li H, Jeschke J, Wang W, Baylin S . Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS One. 2013; 8(7):e68630. PMC: 3701071. DOI: 10.1371/journal.pone.0068630. View

14.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg J, Coleman I, Melchers D . ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019; 35(3):401-413.e6. PMC: 7246081. DOI: 10.1016/j.ccell.2019.01.008. View

15.

Hurd T, Gao L, Roh M, Macara I, Margolis B . Direct interaction of two polarity complexes implicated in epithelial tight junction assembly. Nat Cell Biol. 2003; 5(2):137-42. DOI: 10.1038/ncb923. View

16.

Gao H, Ouyang X, Banach-Petrosky W, Gerald W, Shen M, Abate-Shen C . Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2006; 103(39):14477-82. PMC: 1599986. DOI: 10.1073/pnas.0606836103. View

17.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C . In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995; 9(4):401-6. DOI: 10.1038/ng0495-401. View

18.

Shang X, Lin X, Alvarez E, Manorek G, Howell S . Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia. 2012; 14(10):974-85. PMC: 3479841. DOI: 10.1593/neo.12942. View

19.

Ouban A, Ahmed A . Claudins in human cancer: a review. Histol Histopathol. 2009; 25(1):83-90. DOI: 10.14670/HH-25.83. View

20.

Chakraborty P, Buaas F, Sharma M, Smith B, Greenlee A, Eacker S . Androgen-dependent sertoli cell tight junction remodeling is mediated by multiple tight junction components. Mol Endocrinol. 2014; 28(7):1055-72. PMC: 4075161. DOI: 10.1210/me.2013-1134. View